Impact of cathepsin B-sensitive triggers and hydrophilic linkers onin vitroefficacy of novel site-specific antibody–drug conjugates-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of cathepsin B-sensitive triggers and hydrophilic linkers onin vitroefficacy of novel site-specific antibody–drug conjugates

Published:2018 Issue:11 Volume:16 Page:1882-1889
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Bryden Francesca¹²³⁴,Martin Camille¹²³⁴,Letast Stéphanie¹²³⁴,Lles Eva⁵⁶⁷⁸⁹,Viéitez-Villemin Inmaculada¹²³⁴,Rousseau Anaïs¹²³⁴,Colas Cyril¹⁰⁴,Brachet-Botineau Marie¹¹¹¹²¹³¹⁴,Allard-Vannier Emilie¹⁵³⁴,Larbouret Christel⁵⁶⁷⁸⁹,Viaud-Massuard Marie-Claude¹²³⁴,Joubert Nicolas¹²³⁴^ORCID

Affiliation:

1. UMR7292 GICC CNRS-Université de Tours

2. Team IMT

3. 37200 Tours

4. France

5. U1194 INSERM

6. IRCM

7. Team Immunociblage et radiobiologie en Oncologie

8. ICM

9. 34298 Montpellier

10. UMR7311 ICOA CNRS-Université d'Orléans

11. Team LNOx

12. Faculté de Médecine

13. Bâtiment Dutrochet

14. 37032 Tours

15. EA6295 NMNS Université de Tours

Abstract

Promising anti-HER2 site-specific ADCs with anin vitroefficacy equivalent to Kadcyla®.

Funder

Agence Nationale de la Recherche

Université François-Rabelais

Centre National de la Recherche Scientifique

Ligue Contre le Cancer

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/OB/C7OB02780J

Reference24 articles.

1. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

2. Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer

3. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate

4. Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates

5. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug deconjugation-assisted peptide mapping by LC–MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates;Journal of Pharmaceutical and Biomedical Analysis;2024-06

2. Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates;Pharmacological Reviews;2024-04-15

3. Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment;Journal of Peptide Science;2024-02-21

4. Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer;Journal of Controlled Release;2024-02

5. Potassium 6-Oxo-7,13,16,22-tetraazatetracyclo[12.6.2.18,12.017,21]tricosa-1(20),8(23),9,11,14,16,18,21-octaen-2-yne-15-carboxylate;Molbank;2023-10-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3